- CSR Summary Not yet available
- NCT02951533
- Primary Citation
- Data Specification Not Available
Trial Information
Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaImmune System DiseasesEnrollment119% Female31.1%% White95.8%
Product ClassmAB anti-IL12 and anti-IL23Sponsor Protocol NumberCNTO1959PSO3008Data PartnerJohnson & JohnsonCondition StudiedPsoriasisMean/Median Age (Years)42.4
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0808 : Making Effectiveness Research better by meta-analysing Trial and Real World Evidence in Immune-Mediated inflammatory Diseases (MERMAID)
- 2024-0716 : Validation of causal machine learning methods to identify heterogeneous treatment effects
- 2022-4894 : Systemic pharmacological treatments for chronic plaque psoriasis: A Systematic Review and an Individual-Patient Data Network Meta-Analysis of RCTs